Monthly Archives: February 2024

• 

PRISM study highlights possibility of reducing dose of immunotherapy

By Sharon Deveson Kell|2024-02-15T15:27:30+00:0015 Feb 2024|Drug treatments|

The CheckMate-214 clinical trial was the first study to show [...]

Read More

Comments Off on PRISM study highlights possibility of reducing dose of immunotherapy

• 

World-class radiotherapy in the UK

By Sharon Deveson Kell|2024-02-15T14:49:07+00:0015 Feb 2024|Cancer news|

Led by the All Party Parliamentary Group for Radiotherapy, the [...]

Read More

Comments Off on World-class radiotherapy in the UK

• 

Summary of kidney cancer highlights from ASCO GU 2024

By Sharon Deveson Kell|2024-02-07T08:22:40+00:007 Feb 2024|Drug treatments|

This year’s American Society of Clinical Oncology Genitourinary Cancers (ASCO [...]

Read More

Comments Off on Summary of kidney cancer highlights from ASCO GU 2024

• 

Cancer treatment could identify patients most likely to respond to cancer drugs

By Sharon Deveson Kell|2024-02-02T14:44:09+00:002 Feb 2024|Cancer news|

Scientists from Cancer Research UK and Memorial Sloan Kettering Cancer [...]

Read More

Comments Off on Cancer treatment could identify patients most likely to respond to cancer drugs

• 

Belzutifan and shows better quality of life compared to everolimus

By Sharon Deveson Kell|2024-02-02T09:29:08+00:002 Feb 2024|Drug treatments|

People with kidney cancer have been shown to have changes [...]

Read More

Comments Off on Belzutifan and shows better quality of life compared to everolimus